Advertisement
Document › Details
Evonik. (12/7/20). "Press Release: Fight Against COVID-19. Evonik Supplies Key Technology for Gene-based Drugs". Essen.
Organisation | Evonik (Group) | |
Today | Evonik Industries AG | |
Organisation 2 | Evonik Nutrition & Care GmbH | |
Group | Evonik (Group) | |
Product | lipid nanoparticle technology (LNP technology) | |
Product 2 | mRNA-based drug | |
Person | Riermeier, Thomas (Evonik 202003 SVP + General Manager for Health Care business line) | |
Person 2 | Krauter, Jürgen (Evonik 202003 Head of Commmunications for Nutrition + Care) | |
The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global leader.
> The COVID-19 pandemic has accelerated development of innovative mRNA-based therapies
> Evonik expands its position as integrated solutions provider
> Above-average growth potential for the Health Care business
The COVID-19 pandemic has prompted a breakthrough in gene-based vaccines using a technology in which Evonik is a global leader. Currently, the only established process for transporting mRNA vaccines into the human cell is encapsulation by means of lipid nanoparticles (LNP). Without this protection, the mRNA with the blueprint for stimulating the immune system could not reach the right site of action in the body. Within seconds it would degrade in the bloodstream and make the vaccine ineffective.
“Coping with the pandemic depends largely on the availability of effective vaccines”, says Christian Kullmann, chairman of Evonik's executive board. "The fact that the supply of vaccines is imminent is an outstanding achievement of the pharmaceutical and biotech industry, which we support with highly specialized applications from formulation development to production”. The innovation growth field Healthcare Solutions in the life-science division Nutrition & Care has been growing strongly ever since its formation. For decades, the company has been a leader in the field of drug delivery technologies, which includes lipid nanoparticles. “We are now consistently expanding this position as a solutions provider and integrated development partner.”
Evonik believes that its drug delivery technologies and services have great potential for above-average growth in vaccines as well as cell and gene therapies. Gene therapies, including those involving mRNA active ingredients and the use of lipid nanoparticles, open up the potential for the Health Care business line to generate revenues in the clear triple-digit millions within the next years.
The COVID-19 pandemic has now greatly accelerated the growth of innovative therapeutic approaches. In addition to the vaccines against COVID-19, which are close to approval, the head of Evonik's Health Care business line, Thomas Riermeier, sees numerous other areas of application on the verge of breakthrough, and Evonik is helping to develop them. "Innovative vaccines against influenza, malaria or HIV are just as conceivable as promising approaches for cancer immunotherapy, the treatment of hereditary diseases or defective genes.” A major step in gene editing is expected within the next five years.
Evonik has supported various COVID-19 vaccine projects, from development to the production of clinical samples. As one of the few integrated development partners for gene-based therapies, Evonik has been involved in over 100 projects in the past years, within various application fields.
"The higher efficacy as well as the significantly shorter development times are advantages of gene-based drug products that are currently becoming particularly apparent. The dynamics of the market show a paradigm shift in the way the industry will develop and produce drugs in the future," says Riermeier. Evonik intends to further expand its leading position as an integrated solutions provider in this market. This includes the marketing of special pharmaceutical excipients such as lipids, the development of formulations, i.e. the combination of excipients and active ingredients, as well as the production of clinical test samples, and the production of commercial quantities. The expansion of clinical production capacities is also being planned, as is the expansion of manufacturing capacities for commercial quantities.
Evonik recognized the potential of gene-based therapeutic approaches early on. For customers worldwide, the specialty chemicals company develops and formulates lipid nanoparticles in Burnaby (BC, Canada) and operates a plant for the production of commercial quantities in Birmingham (AL, USA). "With the acquisition of Burnaby-based Transferra Nanosciences, we deliberately invested in this promising technology in 2016," explains Riermeier. With the acquisition of Wilshire Technologies, a US manufacturer of natural excipients for the pharmaceutical industry, the portfolio was further expanded in early 2020.
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around €2.9 billion in 2019 with about 5,300 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
Contact for business media
Matthias Ruch
Head of External Communications
Phone: +49 201 177 3348
Mobile: +49 174 325 9942
E-Mail: matthias.ruch@evonik.com
Contact for trade media
Dr Jürgen Krauter
Head of Market Communications
Phone: +49 6181 59 6847
Mobile: +49 151 1202 8043
E-Mail: juergen.krauter@evonik.com
Record changed: 2023-06-05 |
Advertisement
More documents for Evonik (Group)
- [1] Evonik. (2/20/24). "Press Release: Evonik Partners with the University of Mainz to Commercialize a New Class of PEG Lipids for Nucleic Acid Delivery". Essen....
- [2] Evonik Industries AG. (6/2/22). "Press Release: Evonik Invests US$220 Million in Partnership with the U.S. Government to Build New Lipid Production Facility for mRNA-based therapies in the U.S.". Essen & Parsipanny, NJ....
- [3] Hovione. (2/25/22). "Press Release: Jean-Luc Herbeaux to Become Hovione CEO". Lisbon....
- [4] Evonik Industries AG. (8/2/21). "Press Release: Evonik Acquires German Biotech Company JeNaCell to Expand Biomaterials Portfolio for New Medical Device Markets". Essen....
- [5] Evonik Industries AG. (6/10/21). "Press Release: Evonik and Stanford University Sign Research Collaboration – Evonik to Market and Develop New Drug Delivery Platform for mRNA and Gene Therapy". Essen....
- [6] Evonik Industries AG. (2/11/21). "Press Release: Evonik Strengthens Strategic Partnership with BioNTech on COVID-19 Vaccine". Essen....
- [7] Evonik Industries AG. (3/17/20). "Press Release: Evonik Achieves Major Biotech Breakthrough with a New Animal-free and Fermentation-based Collagen Platform"....
- [8] Evonik Industries AG. (9/5/19). "Press Release: Evonik Invests in Chinese 3D-printing Start-up Making Medical Implants". Essen & Shanghai....
- [9] Evonik Industries AG. (9/3/19). "Press Release: Evonik Acquires a Surface Modification Technology Platform from Interface Biologics to Further Expand Its Medical Device Capabilities"....
- [10] Evonik Industries AG. (2/12/19). "Press Release: Evonik more than Doubles Venture Capital to Accelerate Innovation. Evonik Has Launched Its Second Venture Capital Fund with a Volume of €150 Millionmillion". Essen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top